Ossification, Heterotopic clinical trials
The registry lists 38 studies for Ossification, Heterotopic across more than 10 countries. 7 are recruiting or about to start. 16 of them are mainly about Ossification, Heterotopic (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-05.
Get an email when these change. Save the Ossification, Heterotopic studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Clementia Pharmaceuticals Inc. (5) · Regeneron Pharmaceuticals (4) · Ashibio Inc (2) · University Hospital, Limoges (2) · Aesculap AG (1) · McGill University Health Centre/Research Institute of the McGill University Health Centre (1) · University of Louisville (1) · Radboud University Medical Center (1)
What is being tested here
Drugs under test in Ossification, Heterotopic studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 2
- Jul 2027To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva · Incyte Corporation
- Nov 2027IL1 Inhibition in FOP · University of California, San Francisco
Who these studies take
Of the 5 Ossification, Heterotopic studies recruiting now, 2 (40%) set no upper age limit and 2 (40%) stop at 75 or younger. 5 (100%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 4 (80%) | 4 (80%) |
| 18 | 5 (100%) | 5 (100%) |
| 30 | 5 (100%) | 5 (100%) |
| 40 | 4 (80%) | 4 (80%) |
| 50 | 4 (80%) | 4 (80%) |
| 65 | 4 (80%) | 4 (80%) |
| 75 | 3 (60%) | 3 (60%) |
| 85 | 3 (60%) | 3 (60%) |
Across all 38 studies, recruiting or not: 32% stop at 75 or younger and 24% at 65; 50% take children; 0% are for women only and 0% for men only; 5% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 38 of 38. search them.
- To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans ProgressivaRecruitingNCT05090891Phase 217 countries
- A Study to Investigate the Safety, Pharmacokinetics (PK), and Efficacy of Garetosmab in Children and Adolescents With Fibrodysplasia Ossificans Progressiva (FOP)Not yet recruitingNCT07559513Phase 3
- Subcutaneous Injection of Sodium Thiosulfate for Ectopic Calcifications or Ossifications. A Pilot StudyRecruitingNCT03582800Phase 21 country
- IL1 Inhibition in FOPRecruitingNCT067245621 country
- The Fibrodysplasia Ossificans Progressiva (FOP) RegistryRecruitingNCT027451581 country
- Continuous Passive Motion Versus Heterotopic OssificationRecruitingNCT05906056Not applicable1 country
- Heterotopic Ossification in Abdominal Incision and Pancreatic CancerNot yet recruitingNCT040494611 country
- A Study of Andecaliximab in People With Spinal Cord Injury at Risk for Bone Growth Outside of the Normal Skeleton.Active, not recruitingNCT07024407Phase 1/21 country
- A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)Active, not recruitingNCT06508021Phase 2/31 country
- Prospective Investigation of Intra-Articular Tranexamic Acid Use in Elective Hip ArthroplastyActive, not recruitingNCT069032991 country
- A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)Active, not recruitingNCT05394116Phase 318 countries
- A Non-Interventional Study of Clinical Characteristics and Mortality of US Patients With Fibrodysplasia Ossificans Progressiva (FOP)CompletedNCT060646561 country
- An Open-Label Extension Study of Palovarotene Treatment in Fibrodysplasia Ossificans Progressiva (FOP)CompletedNCT02279095Phase 25 countries
- Heterotopic Ossification ProphylaxisCompletedNCT04867278Not applicable1 country
- Comparative Analysis of Radiotherapeutic and Medical Procedures for the Prophylaxis of Heterotopic OssificationsCompletedNCT062513491 country
- Fracture and Neurological InjuryWithdrawnNCT05075382
- An Efficacy and Safety Study of Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva.CompletedNCT03312634Phase 311 countries
- Tranexamic Acid Prophylaxis for Heterotopic Ossification in Elbow Fracture-Dislocation SurgeryCompletedNCT06088407Not applicable1 country
- Early Ultrasound Screening of Heterotopic Ossification After Severe Neurological TraumaStatus unknownNCT04934332Not applicable1 country
- Celebrex and HO StudyStatus unknownNCT056489161 country
- Influence of Naproxen on Heterotropic Bone Formation Following Hip ArthroscopyCompletedNCT01539447Early Phase 11 country
- Radiation Therapy for Heterotopic Ossification Prophylaxis Acutely After Elbow TraumaTerminatedNCT00991887Not applicable
- Defining the Pathophysiology of Heterotopic Ossification: A Prospective StudyWithdrawnNCT048670181 country
- HO Prophylaxis Therapy for Distal Humerus FracturesTerminatedNCT03724422Not applicable1 country
- Balance in Patients With Ectopic Bone Tissue After Total Hip ReplacementCompletedNCT052189541 country
- Study to Assess the Efficacy and Safety of Garetosmab in Japanese Adult Patients With Fibrodysplasia Ossificans Progressiva (FOP)WithdrawnNCT04577820Phase 3
- An Efficacy and Safety Study of Palovarotene to Treat Preosseous Flare-ups in FOP SubjectsCompletedNCT02190747Phase 23 countries
- Uncemented Hemiarthroplasty, Radiological Features Comparing Lateral Versus Anterolateral ApproachCompletedNCT03974698Not applicable1 country
- In-Home Evaluation of Episodic Administration of Palovarotene in Fibrodysplasia Ossificans Progressiva (FOP) SubjectsTerminatedNCT02521792Phase 21 country
- A Natural History Study of Fibrodysplasia Ossificans Progressiva (FOP)CompletedNCT023222556 countries
- Treatment of Ectopic Calcification / Ossification With Sodium Thiosulfate (CATSSO)Status unknownNCT039793781 country
- Assessment of Heterotopic Ossification of Elbow Joint in Relation of Serum Uric Acid.CompletedNCT039256881 country
- Activ C European Multicenter StudyCompletedNCT024927245 countries
- Study of Pamidronate for the Prevention of Heterotopic OssificationWithdrawnNCT00262392Not applicable
- Prevention of Heterotopic Ossification With Arcoxia After Total Hip ReplacementCompletedNCT01022190Phase 41 country
- Celecoxib for Primary Prophylaxis of Combat-Related Heterotopic OssificationStatus unknownNCT01631669Not applicable2 countries
- Naproxen for the Prevention of HO After Complex Elbow TraumaWithdrawnNCT00586365Phase 41 country
- Prevention of Ectopic Bone Related Pain and Disability After Hip Replacement Surgery With Peri-Operative IbuprofenCompletedNCT00145730Phase 4